Item 9 Labs (OTC:INLB) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Item 9 Labs (OTC:INLB) from a hold rating to a sell rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Item 9 Labs Corp. is a vertically integrated cannabis operator delivering premium products from its large-scale cultivation and production facilities in the United States. Item 9 Labs Corp. is based in PHOENIX. “

Separately, Noble Financial reissued a buy rating and set a $4.00 price target on shares of Item 9 Labs in a research report on Monday, August 23rd.

Shares of INLB opened at $1.53 on Wednesday. Item 9 Labs has a twelve month low of $0.99 and a twelve month high of $4.03.

About Item 9 Labs

Item 9 Labs Corp. focused on development, manufacturing and distribution of nasal breathing and intra-nasal delivery devices. The Company’s Air Allergy is a discreet personal filter which protects from irritating airborne allergens. Air Sleep/Snore provides drug-free relief for congestion and snoring caused by nasal breathing difficulties.

Featured Article: Market Timing

Get a free copy of the Zacks research report on Item 9 Labs (INLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Item 9 Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Item 9 Labs and related companies with MarketBeat.com's FREE daily email newsletter.